Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Equity (2019 - 2025)

BridgeBio Pharma's Return on Equity history spans 7 years, with the latest figure at 0.33% for Q4 2025.

  • For Q4 2025, Return on Equity fell 4.0% year-over-year to 0.33%; the TTM value through Dec 2025 reached 0.33%, down 4.0%, while the annual FY2025 figure was 0.41%, 3.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.33% at BridgeBio Pharma, down from 0.39% in the prior quarter.
  • Across five years, Return on Equity topped out at 4.09% in Q1 2021 and bottomed at 0.33% in Q4 2025.
  • The 5-year median for Return on Equity is 0.48% (2023), against an average of 0.73%.
  • The largest annual shift saw Return on Equity surged 476bps in 2021 before it plummeted -342bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.78% in 2021, then tumbled by -36bps to 0.49% in 2022, then rose by 7bps to 0.53% in 2023, then decreased by -29bps to 0.37% in 2024, then dropped by -11bps to 0.33% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Return on Equity are 0.33% (Q4 2025), 0.39% (Q3 2025), and 0.43% (Q2 2025).